Pemigatinib suppresses liver fibrosis and subsequent osteodystrophy in mice
The serum FGF23 level increased with liver injury, and FGF23 promoted liver fibrosis. Moreover, pemigatinib alleviated liver fibrosis and hepatic osteodystrophy. These findings suggest that FGF23 mediates the communication between the liver and bone and that FGF23 may be a new therapeutic target for liver fibrosis and subsequent osteodystrophy.
Authors
- Yoshiharu Tsuru
- Taiki Mihara (ORCID: https://orcid.org/0009-0003-1611-8329)
- Tamaki Kurosawa (ORCID: https://orcid.org/0000-0002-8453-1567)
- Yuma Nonoshita
- Yuki Yamakawa (ORCID: https://orcid.org/0009-0006-3788-0517)
- Masatoshi Hori
Institutions
- Life Science Institute (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1097/hc9.0000000000000610
- Citations
- 2
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Smoking Research Foundation
- Japan Society for the Promotion of Science